公开(公告)号：US10759868B2

公开(公告)日：2020-09-01

申请号：US15506643

申请日：2015-09-03

Applicant: CELLECTIS

Inventor： Cècile Schiffer-Mannioui

IPC: C07K16/30 ,  C07K14/735 ,  C07K14/705 ,  C07K14/725 ,  C07K19/00 ,  C12N5/078 ,  C12N5/0783

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a 5T4 monoclonal antibody, conferring specific immunity against 5T4 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as colon, stomach, and ovarian tumors.

公开(公告)号：US10752684B2

公开(公告)日：2020-08-25

申请号：US15329932

申请日：2015-07-29

Applicant: Cellectis

Inventor： Cècile Schiffer-Mannioui

IPC: C07K16/28 ,  C07K16/30 ,  C07K14/705 ,  C07K14/725 ,  C12N5/0783 ,  A61K48/00 ,  A61K35/17 ,  C12N5/10 ,  C12N15/62 ,  A61K39/00 ,  C07K19/00

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a ROR1 monoclonal antibody, conferring specific immunity against ROR1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as breast, colon, lung, and kidney tumors.

公开(公告)号：US10752670B2

公开(公告)日：2020-08-25

申请号：US15575707

申请日：2016-05-20

Applicant: Cellectis

Inventor： Julianne Smith ,  Cècile Schiffer-Mannioui

IPC: C07K14/725 ,  A61K39/00 ,  C07K14/705 ,  C07K14/735 ,  C07K16/30 ,  C12N5/0783 ,  A61K38/00

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a GD3 monoclonal antibody, conferring specific immunity against GD3 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating solid tumors such as melanomas, carcinomas or liquid tumor such as T-cell lymphoblastic leukemia.

公开(公告)号：US10544201B2

公开(公告)日：2020-01-28

申请号：US15329530

申请日：2015-07-29

Applicant: CELLECTIS

Inventor： Cècile Schiffer-Mannioui

IPC: C07K14/705 ,  C07K14/735 ,  C07K16/28

Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs, which are made specific to the antigen ROR1. Such CARs aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen ROR1. The alpha, beta and gamma polypeptides composing these CARs are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer, especially chronic lymphocytic leukemia or solid tumors.